Zhang Jianhua, Yue Kai, Wu Yansheng, Jing Chao, Wang Xudong
Department of Head and Neck Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Tianjin Key Laboratory of Basic and Translational Medicine on Head & Neck Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
PLoS One. 2025 Jun 10;20(6):e0325486. doi: 10.1371/journal.pone.0325486. eCollection 2025.
Papillary thyroid carcinoma (PTC) is the most common endocrine carcinoma in recent years, necessitating more precise risk stratification to accurately identify low-risk patients. Although preliminary evidence exists, studies on lysosomes in PTC are limited. This study utilized multi-omics data from the TCGA database to comprehensively investigate the genomic and biological characteristics of lysosomes in PTC patients and identify lysosome-associated genes (LAGs) linked to PTC prognosis. We developed a LAG scoring system for risk stratification based on the expression levels of risk coefficients and independent prognostic LAG variables. Clinical value was assessed through immune infiltration analysis, pathological subgroup analysis, immunotherapy response, and drug sensitivity prediction. Single-cell sequencing from the GEO database was used to analyze PTC samples, and bioinformatics findings were validated using western blot, qRT-PCR, colony formation, and Transwell assays. A new LAG scoring system was developed based on five prognostic LAGs, with single-cell sequencing revealing their expression in different cell types. The role of one LAG, DNASE2B, in PTC cell cloning, proliferation, and invasion was further confirmed in vitro. This comprehensive study highlights the complex interactions between lysosomes and PTC biology, offering new insights into the role of lysosomes in PTC and identifying potential targets for intervention.
甲状腺乳头状癌(PTC)是近年来最常见的内分泌癌,因此需要更精确的风险分层来准确识别低风险患者。尽管已有初步证据,但关于PTC中溶酶体的研究仍然有限。本研究利用来自TCGA数据库的多组学数据,全面探究PTC患者中溶酶体的基因组和生物学特征,并鉴定与PTC预后相关的溶酶体相关基因(LAG)。我们基于风险系数和独立预后LAG变量的表达水平,开发了一种用于风险分层的LAG评分系统。通过免疫浸润分析、病理亚组分析、免疫治疗反应和药物敏感性预测来评估临床价值。利用来自GEO数据库的单细胞测序分析PTC样本,并通过蛋白质免疫印迹、qRT-PCR、集落形成和Transwell实验验证生物信息学研究结果。基于五个预后LAG开发了一种新的LAG评分系统,单细胞测序揭示了它们在不同细胞类型中的表达。体外实验进一步证实了一种LAG,即DNASE2B,在PTC细胞克隆、增殖和侵袭中的作用。这项综合性研究突出了溶酶体与PTC生物学之间复杂的相互作用,为溶酶体在PTC中的作用提供了新见解,并确定了潜在的干预靶点。